Filters

Reset filters

Settings

Has files: true × Subject: Medicine ×

Search Results

Now showing 1 - 5 of 5
  • ItemRestricted
    Government policies for affordable and accessible quality medicines in the Philippines: did the poor benefit?
    (2012-04) Tabuzo, Floreline Fae S.; Tañedo, Trixia Anne A.; Solon, Jose Orville C.
    Medicine prices in the Philippines are one of the most expensive in the world. This is the reason why the Universally Accessible Cheaper and Quality Medicines Act of 2008 was passed. The goal of the said policy is to increase the accessibility of quality medicines to everyone especially the poor as a part of the national health policy of the country. The Annual Poverty Indicators Survey 2008 is used to empirically test the relationship of government's efforts to reduce the prices of medicines and the social awareness and decision to buy. The study shows that the poor has the greatest tendency to buy the cheaper quality medicines from the government's programs given that they are aware of the existence of such programs. The rich will most likely not subscribe to these programs because they will prefer the branded medicines and other services provided by the private sector. The success of government policies to make quality medicines affordable and accessible is dependent on how the government educates its people especially the poor about the programs they provide. The success of the policy is determined by the increase in the number of households who buy the more atlordable quality medicines.
  • ItemRestricted
    The elderly: drug expenditure patterns and price growth
    (2006-04-05) Marders, Richelle Mari M.; Trinidad, Charmaine B.
    Drug expenditure among elderly has reached 46.4 percent of total health care costs in the Philippines. Many studies have looked at factors that affect the drug pattern expenditure of elderly. This study examines the factors that influence expenditure and price growth of medicines. Data from the 1996 Philippine Elderly Survey (PES) and Price Matrix from the National Drug Price Monitoring Board were used in the analysis. Ordinary Least Square regression· analysis was conducted using drug expenditure as the dependent variable. Independent variables were constructed using predisposing social characteristics, enabling factors and the need for health care. Results show that factors such as age, location, poor health status, medical condition (high blood pressure, diabetes, arthritis, kidney problems and cataracts) have significant effect on the drug expenditure among the elderly. On the other hand, RA 9257 has insignificant effect on the curtailment on the price growth of drugs.
  • ItemRestricted
    Will parallel imports of medicines reduce drug prices in the Philippines?
    (2008-10) Cajulao, Jennifer Euraine; Rubio, Ria Maureen
    This paper examined if parallel importation of pharmaceutical drugs could reduce their local prices. Based on a model of parallel imports developed by Maskus and Ganslandt, the authors used regression analysis to explain drug prices with parallel imports of pharmaceutical products and other relevant independent variables. Results showed that drug prices appeared to decline with parallel imports of selected drugs by the Philippine International Trading Corporation. The coefficient of parallel imports in the regression equation is negative, albeit insignificant at the 5% level. This result may be due to the limited quantity that PITC brought into the country from India. With the possible liberalization of parallel drug imports under the proposed Quality Affordable Medicines Act of 2007, their full effect in reducing drug prices in the Philippines may be realized as Maskus and Ganslandt documented in the case of the European Union.
  • ItemRestricted
    Access denied: a theoretical analysis of the cheaper medicines law
    (2009-01) Badilla, Mary Frances O.; Tiu, Clarens Susan Y.
    The Universally Accessible and Cheaper Medicines Act of 2008 (Cheaper Medicines Law) was implemented in response to the high prices of medicines in the Philippines. The Maximum Drug Price Policy, a major provision of the law, imposed price ceilings on five essential drugs. This paper aimed to determine whether a substantial increase in drug accessibility will be achieved. With the use of theoretical analysis, three cases were formed based on the nature of the markets of the essential drugs: monopoly, oligopoly and monopolistic competition. The behaviours of the branded drugs market and generics market in each situation were also depicted in graphs to aid in better analysis. Findings show that the law will increase drug accessibility in the short run but not so in the long run as an anti-competitive market environment ensues. Only the higher and middle-income classes are largely benefitted by the lower prices while the lower-income classes continue to lack access to these drugs. Thus, the Cheaper Medicines Law is declared ineffective in providing a substantial increase in drug accessibility.
  • ItemRestricted
    An assessment of the implementation process of the Generics Act of 1988
    (1993-03-22) Bautista, Marie Dell L.; Gumagay, Hennie Fe O.; Herrin, Alejandro N.
    This paper examines the implementation process of the Generics Act of 1988. The paper determines whether the measures or mechanisms employed by the implementing agencies were adequate or effective to carry out and ensure the fulfillment of the policy's intention. To go about the evaluation, a criteria was made based upon the government actions. How far these mechanisms have thus achieved what they were supposed to do will be evaluated upon the criteria. Results of the surveys conducted by the Department of Health, the Bureau of Food and Drugs, and the Philippine Information Agency indicate the extent of the mechanisms' impact, and were hence used in the exploratory study as well as other relevant data in statistical yearbooks and reports. The study revealed that, although some mechanisms proved to be satisfactory, still others were inadequate to a certain degree. These inadequate mechanisms probably explains why the Generics Act has not been able to go much far since its full implementation. For the Act to work out, these measures need to.be strengthened and reinforced.